Love Your Location

Why one of the world's leading life science companies chose Pearland

The Lonza facility in Lower Kirby. Photo courtesy of Pearland Economic Development Corp.

In 2018, Switzerland-based company Lonza debuted a 300,000-square-foot life science facility in Pearland, the largest dedicated cell and gene therapy manufacturing facility in the world at the time.

What made one of the world's largest companies for contract development and manufacturing choose Lower Kirby for this groundbreaking building?

"The location was ideal for the expansion capability, proximity to the Texas Medical Center, and ease of access from major freeways 288 and Beltway 8," says Frank Bugg, Lonza's site head. "Many Lonza employees also reside in the Pearland area."

The company also sought a location for this "Center of Excellence" that would maintain a presence on the "third coast" of biotech. Lonza currently employs more than 500 at its Pearland facility.

Additional factors that made Pearland's Lower Kirby District an attractive choice for Lonza were the nearby life sciences community, infrastructure, and quality-of-life benefits such as top-rated schools and a reasonable cost of living.

The team at this location is currently leading efforts in four categories: research and development, process development, cell and gene therapy manufacturing, and viral vector manufacturing.

Cell and gene therapy is growing and these novel medicines are getting established as a validated treatment option — the field is transforming the way cancer or genetic diseases can be treated.

In 2019, Lonza provided manufacturing services for more than 300 commercial molecules and supported the development of more than 700 pre-clinical and clinical molecules in small and large molecules, as well as supporting the launch of pioneering autologous cell therapies.

These novel drug candidates provide drastically improved patient outcomes and, in some cases, can be curative. However, manufacturing of such medicines pose complex new challenges.

Today, the cost of production still represents a major hurdle for clinical translation and commercialization of these potentially groundbreaking therapies. New technologies are needed to enable robust and cost-efficient manufacturing of high-quality medicines.

While the therapeutic opportunities for patients are exciting, the stakes for patients and drug developers are high.

Lonza serves as a partner to its customers, keeping manufacturing costs under control and following the process through the regulatory bodies through to commercialization.

The company also helps develop and commercialize its customers' innovative new therapies. Lonza scientists and engineers bring decades-long development experience across a broad spectrum of cell types and technologies. With this background, they can tailor services in process and analytical development, manufacturing, and regulatory support.

The work done at Lonza is at the forefront of medical breakthroughs. These cell and gene therapies are shaping the way we treat modern diseases, and now it's being done right in Houston's own backyard.

Since the Pearland facility's opening in 2018, Lonza has continued to expand with the addition of laboratories, clean rooms, and additional parking.

Trending News

Building Houston

 
 

Capital Factory's Houston HQ will be in The Ion. Photo courtesy of The Ion

A company that supports entrepreneurship and startups across the Lone Star State with mentorship and funding has announced its new homebase in Houston.

Capital Factory has revealed a new programming partnership with The Ion. Through the collaboration, Capital Factory will host programming, events, and resources within the innovation hub to grow, educate, and support Houston-based startups and entrepreneurs.

"Capital Factory's presence at The Ion will further expand the opportunities for startups and innovators in the Houston region, while strengthening an important pillar of the Texas Startup Manifesto," says Joshua Baer, founder and CEO of Capital Factory, in a news release.

Capital Factory was founded in Austin in 2009 and boosts on being the most active investor in Texas, deploying smaller investments to a multitude of early-stage startups. According to Crunchbase's data, the entity has invested in over 160 companies with 20 exits. Capital Factory officially entered the Houston market in 2019 and doubled down its presence last year when it merged with Station Houston.

Now, with its Houston headquarters moving into The Ion, the two innovation partners will take an inclusive approach to creating connections between innovators, mentors, investors, and markets, per the release.

"We are thrilled to have Capital Factory as a programming partner at The Ion" says Jan E. Odegard, executive director of The Ion, in the release. "The Ion seeks to work with key partners and established brands to help build a rich and inclusive set of startup services that can support all innovators and startups wherever they are in their entrepreneurial journey. Capital Factory brings a proven track record for providing entrepreneurs with services and investments that brings great value not only to The Ion ecosystem, but also to the entire Houston innovation ecosystem."

Capital Factory's first event at The Ion will be Open Coffee on November 16th followed by Open Coworking all day, Baer adds in his statement.

Trending News